Global CRO Compliance & Auditing Services

 The convergence of biostatistics, compliance, and regulatory inspection readiness is crucial in clinical development. Statistical outputs now serve as documented, reproducible, and auditable evidence rather than being merely correct or incorrect. With growing scrutiny from global regulators regarding statistical computing, analysis traceability, and adherence to standards like CDISC ADaM, biostatistics teams face pressure to demonstrate data and process integrity. This article explores key compliance risk areas in 2026 and discusses how specialized audit and compliance services can aid sponsors and CROs in navigating this landscape.

The FDA’s Office of Biostatistics is crucial in drug and biologic reviews, assessing the alignment of study designs with clinical and regulatory questions, the reliability of endpoints, the suitability of analyses, and the robustness of findings. Sponsors must show that their statistical methods are scientifically valid, documented, verifiable, and in compliance with global regulatory data integrity standards.

auditcompliancebiostatisticsservicesforregulatoryinspections.png
How CurexBio Delivers Audit & Compliance Biostatistics Services
CurexBio provides biostatistics services tailored to fulfill FDA, EMA, and CDSCO requirements for audit readiness and regulatory compliance, ensuring embedded statistical integrity from study design to final submission.

Statistical Analysis Plan (SAP)
CurexBio biostatistician develops Statistical Analysis Plan (SAP) that adhere to the ICH E9(R1) estimand framework, detailing analysis populations, handling of intercurrent events, and statistical models. These plans are designed to endure regulatory scrutiny, ensuring a clear link from protocol objectives to final analysis outputs.

CDISC-Compliant SDTM and ADaM Datasets
Our biostatistics team creates submission-ready SDTM and ADaM datasets that meet FDA and CDISC standards, along with validated Define-XML files for traceability of variables and derivations, enhancing the technical review process and minimizing submission queries.

Risk-Based Compliance for CSA and ICH E6(R3)
We align our services with the FDA’s final Computer Software Assurance (CSA) guidance through a risk-based approach to software validation, documenting essential aspects for high-risk components while ensuring regulatory compliance. Our quality management system incorporates ICH E6(R3) principles, identifying critical-to-quality factors and applying appropriate controls in statistical processes.

Traceable Programming and TLF Generation
All tables, listings, and figures are created using version-controlled programming scripts, ensuring traceability from analysis specifications to final outputs. This allows for verification of results by inspectors. The programming teams adhere to Good Programming Practices, focusing on readability, documentation, and reproducibility.

Inspection Support and Mock Audits
CurexBio provides mock regulatory inspections that emphasize biostatistics and data integrity, assisting sponsors in identifying gaps prior to regulatory reviews. Their services include preparing documentation for inspections, conducting pre-audit assessments of statistical processes, and offering on-call statisticians and programmers during live inspections.

CurexBio provides the audit‑ready framework for your statistical submissions. Our expert biostatisticians and programmers deliver inspection‑ready analyses and datasets that satisfy even the most rigorous regulatory reviewers.

Get Inspection‑Ready With CurexBio . Contact us for consultation on audit-ready biostatistics, CDISC compliance, CSA-aligned validation, and inspection support services to ensure regulatory submission success.